Projects
A controlled phase II clinical trial evaluating efficacy of myelin peptide-loaded tolDC as treatment for MS. University of Antwerp
Oncocidia_the novel anticancer therapy: phase 0 clinical study. KU Leuven
Cancer residue, common after current therapies, remains a culprit for recurrence and patient death. To solve this problem, the group of Prof. Y. Ni at KU Leuven has developed a new dual targeting anticancer strategy, called Oncocidia. It is based on the subsequent injection of two compounds – a vascular disruptive agent and a radiolabeled necrosis-avid compound- which have a highly synergistic effect. The therapy has been extensively tested ...
A randomized phase II clinical trial in NSCLC combining SBRT and I.V. anti-PD-1 with or without I.T. anti-CTLA-4/anti-PD-L1 plus CD1c+ myDC Vrije Universiteit Brussel
Establishing safety and efficacy of an improved Asparaginase in dog models: final preparation for Phase I clinical trial Ghent University
We designed a novel stabilized humanized asparaginase with clinically relevant pharmacokinetic properties that has significantly reduced toxicity, but similar anti-leukemic properties compared to the asparaginase formulations that are nowadays used in the clinic to treat pediatric and adult acute lymphoblastic leukemia (manuscript in preparation). This project aims to validate the safety and efficacy of our newly designed asparaginase in a ...
Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer KU Leuven
IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of radiation observed at distance from the ...
Arm-hand BOOST therapy to enhance recovery after stroke in the sub-acute phase after stroke: clinical evaluation up to one year post-stroke KU Leuven
Deficits in arm and hand movements after stroke are common and result in reduced independence in activities of daily living and quality of life. Implementable therapy in the subacute rehabilitation phase for improved arm and hand recovery long-term after stroke that demonstrates robust benefits for patient and society is still required. This is what our project will investigate, specifically whether for P: patients after stroke, who are ...
Phase I/II clinical trial on autologous cancer-testis antigen targeted dendritic cell immunotherapy (TriMixDC) for patients with inoperable pretreated colorectal cancer Ghent University
2012-206: Phase I/II clinical trial on autologus cancer-testis antigen targeted dendritic cell immunotherapy (TriMixDC) for patients with inoperable pretreated colorectal cancer
Stichting tegen Kanker
2012-206
Pre-delivery administration of azithromycin to prevent neonatal sepsis and death: a phase III double-blind randomized clinical trial Institute of Tropical Medicine
maternal and 4 million neonatal deaths every year and half of them occur in sub-Saharan Africa.
Bacterial infections, namely sepsis, are a leading cause of maternal and neonatal deaths in sub-Saharan Africa. Newborns
can be infected during labour - when passing through the birth canal - and also during the ...